M&A: Range of Fundamental Factors Will Drive Strong Deal Flow

Apr 2nd 2019 Author:

Michael Jewell

View Profile

Last year proved to be a bumper year for pharmaceutical mergers and acquisitions (M&A) with over $265bn worth of deals globally in life sciences alone, an increase of 26% on 2017. This was against a backdrop of strong global M&A with the total value of deals amounting to $3.8 trillion in the year. Mega-deals dominated as the largest pharmaceutical firms looked to increase their pipeline of innovative drugs particularly within biopharma. Companies focused on oncology and gene therapy were among the most attractive targets.

Read full article in Pharma Exec